Browsing Tag
David Cade
1 post
Brain cancer breakthrough? Telix Pharmaceuticals’ TLX101 boosts survival in early study as stock outlook strengthens
Discover how Telix’s TLX101 therapy is showing new promise for brain cancer as investor sentiment rises with key study results and clinical trial expansion.